Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: A review

N. Savage, T. I. George, J. Gotlib

Research output: Contribution to journalReview article

40 Citations (Scopus)

Abstract

Summary: Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of platelet-derived growth factor receptor alpha (PDGFRA), platelet-derived growth factor receptor beta (PDGFRB), and fibroblast growth factor receptor-1 (FGFR1) are a group of hematologic neoplasms resulting from the formation of abnormal fusion genes that encode constitutively activated tyrosine kinases. These entities are now separated into their own major category in the 2008 World Health Organization classification of hematolymphoid tumors. Although eosinophilia is characteristic of these diseases, the clinical presentation of the three entities is variable. Conventional cytogenetics (karyotyping) will detect the majority of abnormalities involving PDGFRB and FGFR1, but florescence in situ hybridization (FISH)/molecular studies are required to detect factor interacting with PAP (FIP1L1)-PDGFRA as the characteristic 4q12 interstitial deletion is cryptic. Imatinib mesylate (imatinib) is the first-line therapy for patients with abnormalities of PDGFRA/B, whereas patients with FGFR1 fusions are resistant to this therapy and carry a poor prognosis. The discovery of novel gene rearrangements associated with eosinophilia will further guide our understanding of the molecular pathobiology of these diseases and aid in the development of small-molecule inhibitors that inhibit deregulated hematopoiesis.

Original languageEnglish (US)
Pages (from-to)491-500
Number of pages10
JournalInternational Journal of Laboratory Hematology
Volume35
Issue number5
DOIs
StatePublished - Oct 1 2013

Fingerprint

Receptor, Fibroblast Growth Factor, Type 1
Platelet-Derived Growth Factor alpha Receptor
Platelet-Derived Growth Factor beta Receptor
Eosinophilia
Fusion reactions
Genes
Karyotyping
Neoplasms
Gene Rearrangement
Gene Fusion
Hematopoiesis
Hematologic Neoplasms
Cytogenetics
Protein-Tyrosine Kinases
In Situ Hybridization
Tumors
Health
Molecules
Therapeutics
Imatinib Mesylate

Keywords

  • CHIC2
  • Eosinophilia
  • FGFR1
  • PDGFRA
  • PDGFRB

ASJC Scopus subject areas

  • Hematology
  • Clinical Biochemistry
  • Biochemistry, medical

Cite this

Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1 : A review. / Savage, N.; George, T. I.; Gotlib, J.

In: International Journal of Laboratory Hematology, Vol. 35, No. 5, 01.10.2013, p. 491-500.

Research output: Contribution to journalReview article

@article{624047a6aa9c417fad131318b3635fb8,
title = "Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1: A review",
abstract = "Summary: Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of platelet-derived growth factor receptor alpha (PDGFRA), platelet-derived growth factor receptor beta (PDGFRB), and fibroblast growth factor receptor-1 (FGFR1) are a group of hematologic neoplasms resulting from the formation of abnormal fusion genes that encode constitutively activated tyrosine kinases. These entities are now separated into their own major category in the 2008 World Health Organization classification of hematolymphoid tumors. Although eosinophilia is characteristic of these diseases, the clinical presentation of the three entities is variable. Conventional cytogenetics (karyotyping) will detect the majority of abnormalities involving PDGFRB and FGFR1, but florescence in situ hybridization (FISH)/molecular studies are required to detect factor interacting with PAP (FIP1L1)-PDGFRA as the characteristic 4q12 interstitial deletion is cryptic. Imatinib mesylate (imatinib) is the first-line therapy for patients with abnormalities of PDGFRA/B, whereas patients with FGFR1 fusions are resistant to this therapy and carry a poor prognosis. The discovery of novel gene rearrangements associated with eosinophilia will further guide our understanding of the molecular pathobiology of these diseases and aid in the development of small-molecule inhibitors that inhibit deregulated hematopoiesis.",
keywords = "CHIC2, Eosinophilia, FGFR1, PDGFRA, PDGFRB",
author = "N. Savage and George, {T. I.} and J. Gotlib",
year = "2013",
month = "10",
day = "1",
doi = "10.1111/ijlh.12057",
language = "English (US)",
volume = "35",
pages = "491--500",
journal = "International Journal of Laboratory Hematology",
issn = "1751-5521",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Myeloid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, and FGFR1

T2 - A review

AU - Savage, N.

AU - George, T. I.

AU - Gotlib, J.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Summary: Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of platelet-derived growth factor receptor alpha (PDGFRA), platelet-derived growth factor receptor beta (PDGFRB), and fibroblast growth factor receptor-1 (FGFR1) are a group of hematologic neoplasms resulting from the formation of abnormal fusion genes that encode constitutively activated tyrosine kinases. These entities are now separated into their own major category in the 2008 World Health Organization classification of hematolymphoid tumors. Although eosinophilia is characteristic of these diseases, the clinical presentation of the three entities is variable. Conventional cytogenetics (karyotyping) will detect the majority of abnormalities involving PDGFRB and FGFR1, but florescence in situ hybridization (FISH)/molecular studies are required to detect factor interacting with PAP (FIP1L1)-PDGFRA as the characteristic 4q12 interstitial deletion is cryptic. Imatinib mesylate (imatinib) is the first-line therapy for patients with abnormalities of PDGFRA/B, whereas patients with FGFR1 fusions are resistant to this therapy and carry a poor prognosis. The discovery of novel gene rearrangements associated with eosinophilia will further guide our understanding of the molecular pathobiology of these diseases and aid in the development of small-molecule inhibitors that inhibit deregulated hematopoiesis.

AB - Summary: Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of platelet-derived growth factor receptor alpha (PDGFRA), platelet-derived growth factor receptor beta (PDGFRB), and fibroblast growth factor receptor-1 (FGFR1) are a group of hematologic neoplasms resulting from the formation of abnormal fusion genes that encode constitutively activated tyrosine kinases. These entities are now separated into their own major category in the 2008 World Health Organization classification of hematolymphoid tumors. Although eosinophilia is characteristic of these diseases, the clinical presentation of the three entities is variable. Conventional cytogenetics (karyotyping) will detect the majority of abnormalities involving PDGFRB and FGFR1, but florescence in situ hybridization (FISH)/molecular studies are required to detect factor interacting with PAP (FIP1L1)-PDGFRA as the characteristic 4q12 interstitial deletion is cryptic. Imatinib mesylate (imatinib) is the first-line therapy for patients with abnormalities of PDGFRA/B, whereas patients with FGFR1 fusions are resistant to this therapy and carry a poor prognosis. The discovery of novel gene rearrangements associated with eosinophilia will further guide our understanding of the molecular pathobiology of these diseases and aid in the development of small-molecule inhibitors that inhibit deregulated hematopoiesis.

KW - CHIC2

KW - Eosinophilia

KW - FGFR1

KW - PDGFRA

KW - PDGFRB

UR - http://www.scopus.com/inward/record.url?scp=84884979496&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884979496&partnerID=8YFLogxK

U2 - 10.1111/ijlh.12057

DO - 10.1111/ijlh.12057

M3 - Review article

C2 - 23489324

AN - SCOPUS:84884979496

VL - 35

SP - 491

EP - 500

JO - International Journal of Laboratory Hematology

JF - International Journal of Laboratory Hematology

SN - 1751-5521

IS - 5

ER -